Drug Use Investigation for REVOLADE (ITP)

• Status: Completed
• Trial end date: 2020-10-16
• Target enrollment: 0
• Participant gender: All

Summary

To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy.Thromboembolism Accepts Healthy Volunteers? No

Details

• Lead Sponsor: Novartis; Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Subjects with chronic idiopathic thrombocytopenic purpura

Exclusion Criteria:

• Not applicable